Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.

Melanoma research·2026
Same author

Mastering Organoid Growth: A Complete Guide to Overcoming Methodological Challenges.

MedComm·2026
Same author

MCL1 may not mediate chemoresistance.

bioRxiv : the preprint server for biology·2025
Same author

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.

Nature medicine·2025
Same author

TET2 regulates early and late transitions in exhausted CD8<sup>+</sup> T cell differentiation and limits CAR T cell function.

Science advances·2024
Same journal

CAR T cells: The next frontier.

Cytotherapy·2026
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Tumor vaccines and beyond.

Jan Joseph Melenhorst1, Austin John Barrett

  • 1Stem Cell Allogeneic Transplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cytotherapy
|November 12, 2010
PubMed
Summary
This summary is machine-generated.

Tumor vaccines show variable success in treating cancers. This review examines past immunotherapy strategies to improve anti-tumor responses for more patients.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jun 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immunotherapy, particularly tumor vaccines, has yielded inconsistent results in treating solid and hematopoietic tumors over the past 20 years.
  • Current successes in cancer immunotherapy are often limited to a small subset of patients, highlighting a need for broader efficacy.

Purpose of the Study:

  • To critically review the field of tumor vaccines and immunotherapy for solid and hematopoietic tumors.
  • To identify factors contributing to both successful and unsuccessful anti-tumor immune responses.
  • To propose strategies for enhancing the efficacy of cancer immunotherapy to benefit a larger patient population.

Main Methods:

  • Comprehensive literature review of studies on tumor vaccines and cancer immunotherapy.
  • Analysis of methodologies used to assess anti-tumor immune responses.
  • Evaluation of clinical outcomes and immunological data from various treatment approaches.

Main Results:

  • Certain immunotherapy strategies have demonstrated efficacy, while others have shown limited or no benefit.
  • Understanding the mechanisms of immune evasion and resistance is crucial for improving treatment outcomes.
  • Standardized methods for evaluating anti-tumor responses are needed to better compare different vaccine approaches.

Conclusions:

  • Past tumor vaccine trials offer valuable lessons for developing more effective cancer immunotherapies.
  • Future strategies should focus on overcoming immune suppression and enhancing T-cell mediated anti-tumor immunity.
  • Improving the success rate of cancer immunotherapy requires a deeper understanding of tumor-immune interactions and patient-specific factors.